$Applied Genetic(AGTC)$ Applied Genetic Technologies shares are trading higher after the company announced that it plans to release 12-month data for adult patients and low-dose pediatric patients in its Phase 1/2 clinical Achromatopsia trials on Thursday, June 24, 2021.